Designing a strategy to realize the potential of rAAV vectors in gene therapy and genetic vaccinations
Expert Insight: Designing a strategy to realize the potential of rAAV vectors in gene therapy and genetic vaccinations
Watch this on-demand webinar to learn how LC and LC-MS technologies are being applied to the analysis of rAAV viral vectors
09 Feb 2021
Principal scientist Stephan M. Koza and senior scientist Ximo Zhang, Waters
Recombinant adeno-associated viral (rAAV) vectors have emerged as the leading gene delivery platform for gene therapy and genetic vaccination. For this promising gene delivery vector to fully realize its therapeutic or prophylactic potential, a rational design strategy is desired. The current challenges in viral vector manufacturing: robustness, scale-up, and productivity will need to be addressed to turn this mode of treatment into an accessible global benefit. To meet this goal, reliable analytical technologies are needed to help establish a struc